leadf
logo-loader
viewQ BioMed Inc.

Q BioMed Inc. launches program to bring metastatic bone pain drug Strontium89 to the EU and elsewhere

The Named Patient Program allows Strontium89 to be provided to patients internationally without needing additional regulatory approval in their countries

Person sitting with hands on knee overlayed with leg bone graphic
Strontium89 is administered intravenously once every three months and can reduce or even eliminate the need for opioid analgesics

Q BioMed Inc (OTCQB:QBIO) has launched a Named Patient Program (NPP) to bring its non-opioid bone metastasis pain drug Strontium89 to patients around the world starting in September, the company announced on Tuesday.

Strontium89 is FDA-approved for the treatment of painful skeletal metastases caused by cancer, regardless of the type of tumor. Common cancers that metastasize to the bone include prostate, breast, lung and others.

The NPP allows Strontium89 to be provided to patients internationally without needing additional regulatory approval in their countries. It will be facilitated by Caligor Coghlan Pharma Services, a global pharmaceuticals company based in Texas.

READ: Q Biomed to scale-up production of potential liver cancer chemotherapeutic Uttroside-B as it gears up for IND filing

"We are very happy that Strontium89 is once again available worldwide, and that physicians have the ability to prescribe a safe, effective and non-opioid treatment to their be metastasis pain patients regardless of their primary tumor type and notably beyond prostate cancer,” Q BioMed CEO Denis Corin said in a statement. “We are actively working to ensure that Strontium89 is accessible to patients everywhere and to extend its relevance and use thorough additional clinical study."

Strontium89 is administered intravenously once every three months and can reduce or even eliminate the need for opioid analgesics, the company said, delivering pain relief for 2-5 months in most patients.

In several multicenter, placebo-controlled trials of cancer patients with pain from bone metastases, relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Q BioMed Inc.

Price: 0.9405 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $22.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Q BioMed's bone pain drug Strontium89 sees Medicare reimbursement rate upped

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the Centers for Medicare and Medicaid Services (CMS) updated the reimbursement rate for its metastatic bone pain drug Strontium89, making it more easily available to Medicare patients. Corin says with the CMS update, all Medicare...

5 days, 16 hours ago

2 min read